Report of Foreign Issuer (6-k)
May 14 2020 - 7:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
For the month of May 2020
Commission File Number: 001-37643
KITOV PHARMA LTD.
(Translation of registrant’s name
into English)
One Azrieli Center, Round Tower,
132 Menachem Begin Road, Tel Aviv 6701101,
Israel
(Address of principal executive offices)
Indicate by check mark
whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov
Pharma Ltd. (the “Company” or the “Registrant”) is announcing that on February 10, 2019, the Company issued
a press release, “Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical
Oncology 2020 Virtual Scientific Program”, which is attached hereto as Exhibit 99.1.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
KITOV PHARMA LTD.
|
|
|
|
May 14, 2020
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
CEO & Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2024 to May 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From May 2023 to May 2024